• Explore /
  • Poster
  • / Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.

Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.

Abstract Video & Slides Poster

Authors

null

Keisho Chin

Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Keisho Chin , Ken Kato , Byoung Chul Cho , Masanobu Takahashi , Morihito Okada , Chen-Yuan Lin , Shigenori Kadowaki , Myung-Ju Ahn , Yasuo Hamamoto , Yuichiro Doki , Chueh-Chuan Yen , Yutaro Kubota , Sung-Bae Kim , Chih-Hung Hsu , Eva Holtved , Ioannis Xynos , Yasuhiro Matsumura , Akira Takazawa , Yuko Kitagawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02569242

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 204)

DOI

10.1200/JCO.2021.39.3_suppl.204

Abstract #

204

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Kuaile Zhao

First Author: Nick Pavlakis

First Author: Sarmad Sadeghi

First Author: Jonathan E. Rosenberg